Azioni Bristol Myers Squibb Co. (BMY) — è una buona azienda?

Azioni Bristol Myers Squibb Co. (BMY) — è una buona azienda? — InspectStocks

Come guadagna

Prescription medicines, plus royalties and alliance-related revenue100%

Le quote di ricavo sono stime per FY2025, non cifre tratte da un documento depositato.

Compete con

Che cosa vende6

Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.

Mostra altri 3

Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.

Chi lo compra5

Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
Retail pharmacies, hospitals and clinics that purchase or dispense medicines.

Mostra altri 2

Government agencies and public health programs that buy medicines or cover their cost.
Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).
4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.
5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.

Che cosa potrebbe andare storto

1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.

Bilanci completi →

Informazioni su Bristol Myers Squibb Co.

Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.

Sede: Lawrence Township, New Jersey (Princeton area)
Fondata nel: 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
Dipendenti: Approximately 32,500 (December 31, 2025, high)
Quotata su: NYSE
Chiusura dell'esercizio: December 31

Costruito dai documenti depositati da Bristol Myers Squibb Co. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.

Keep exploring

The themes Bristol Myers Squibb is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Come guadagna

Prescription medicines, plus royalties and alliance-related revenue100%

Le quote di ricavo sono stime per FY2025, non cifre tratte da un documento depositato.

Compete con

Che cosa vende6

Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.

Mostra altri 3

Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.

Chi lo compra5

Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
Retail pharmacies, hospitals and clinics that purchase or dispense medicines.

Mostra altri 2

Government agencies and public health programs that buy medicines or cover their cost.
Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).
4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.
5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.

Che cosa potrebbe andare storto

1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.

Bilanci completi →

Informazioni su Bristol Myers Squibb Co.

Sede: Lawrence Township, New Jersey (Princeton area)
Fondata nel: 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
Dipendenti: Approximately 32,500 (December 31, 2025, high)
Quotata su: NYSE
Chiusura dell'esercizio: December 31

Come guadagna

Compete con

Che cosa vende6

Chi lo compra5

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Bristol Myers Squibb Co.

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Come guadagna

Compete con

Che cosa vende6

Chi lo compra5

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Bristol Myers Squibb Co.

Bristol Myers Squibb Co.

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Crescita e cassa — 3 su 5

Andamento dell'attività

Prezzo dell’azione e voto nel tempo

Come guadagna

Compete con

Che cosa vende6

Chi lo compra5

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Bristol Myers Squibb Co.

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Come guadagna

Compete con

Che cosa vende6

Chi lo compra5

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

Che cosa potrebbe andare storto

Informazioni su Bristol Myers Squibb Co.

Bristol Myers Squibb Co.

Andamento passato

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Crescita e cassa — 3 su 5

Andamento dell'attività

Prezzo dell’azione e voto nel tempo